Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

27-Hydroxycholesterol: the first identified endogenous SERM.

Umetani M, Shaul PW.

Trends Endocrinol Metab. 2011 Apr;22(4):130-5. doi: 10.1016/j.tem.2011.01.003. Review.

2.

Re-adopting classical nuclear receptors by cholesterol metabolites.

Umetani M.

J Steroid Biochem Mol Biol. 2016 Mar;157:20-6. doi: 10.1016/j.jsbmb.2015.11.002. Review.

3.

Breast cancer and (25R)-26-hydroxycholesterol.

Javitt NB.

Steroids. 2015 Dec;104:61-4. doi: 10.1016/j.steroids.2015.08.012. Review.

PMID:
26299212
4.

Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.

Lewis JS, Jordan VC.

Mutat Res. 2005 Dec 11;591(1-2):247-63. Review.

PMID:
16083919
5.

Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance.

Sengupta S, Jordan VC.

Adv Exp Med Biol. 2008;630:206-19. Review.

PMID:
18637493
6.

Selectively targeting estrogen receptors for cancer treatment.

Shanle EK, Xu W.

Adv Drug Deliv Rev. 2010 Oct 30;62(13):1265-76. doi: 10.1016/j.addr.2010.08.001. Review.

7.

Structure-function relationship of estrogen receptors in cardiovascular pathophysiological models.

Arnal JF, Valéra MC, Payrastre B, Lenfant F, Gourdy P.

Thromb Res. 2012 Oct;130 Suppl 1:S7-11. doi: 10.1016/j.thromres.2012.08.261. Review.

PMID:
23026669
8.

Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

Park WC, Jordan VC.

Trends Mol Med. 2002 Feb;8(2):82-8. Review.

PMID:
11815274
9.

Cholesterol and breast cancer pathophysiology.

Nelson ER, Chang CY, McDonnell DP.

Trends Endocrinol Metab. 2014 Dec;25(12):649-55. doi: 10.1016/j.tem.2014.10.001. Review.

10.

Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases.

Thomas T, Gallo MA, Thomas TJ.

Curr Cancer Drug Targets. 2004 Sep;4(6):483-99. Review.

PMID:
15379634
11.

Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.

Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K, Katzenellenbogen JA.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):279-85. Review.

PMID:
11162936
12.

Selective estrogen receptor modulators: an update on recent clinical findings.

Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB.

Obstet Gynecol Surv. 2008 Mar;63(3):163-81. doi: 10.1097/OGX.0b013e31816400d7. Review.

PMID:
18279543
13.

The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

Lee WL, Cheng MH, Chao HT, Wang PH.

Taiwan J Obstet Gynecol. 2008 Mar;47(1):24-31. doi: 10.1016/S1028-4559(08)60051-0. Review.

14.

Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

Jordan VC, O'Malley BW.

J Clin Oncol. 2007 Dec 20;25(36):5815-24. Review.

PMID:
17893378
15.

[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].

Maeda T, Ke HZ, Simmons H, Thompson D.

Clin Calcium. 2004 Oct;14(10):85-93. Review. Japanese.

PMID:
15577137
16.
17.

Estrogen receptor beta in breast cancer.

Palmieri C, Cheng GJ, Saji S, Zelada-Hedman M, Wärri A, Weihua Z, Van Noorden S, Wahlstrom T, Coombes RC, Warner M, Gustafsson JA.

Endocr Relat Cancer. 2002 Mar;9(1):1-13. Review.

18.

Regulation of specific target genes and biological responses by estrogen receptor subtype agonists.

Leitman DC, Paruthiyil S, Vivar OI, Saunier EF, Herber CB, Cohen I, Tagliaferri M, Speed TP.

Curr Opin Pharmacol. 2010 Dec;10(6):629-36. doi: 10.1016/j.coph.2010.09.009. Review.

19.

Estrogen receptors as therapeutic targets in breast cancer.

Ariazi EA, Ariazi JL, Cordera F, Jordan VC.

Curr Top Med Chem. 2006;6(3):181-202. Review.

PMID:
16515478
20.

Molecular mechanisms of selective estrogen receptor modulator (SERM) action.

Dutertre M, Smith CL.

J Pharmacol Exp Ther. 2000 Nov;295(2):431-7. Review.

Supplemental Content

Support Center